Back to search

Article

<i>HSD3B1</i> genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisone

2025-09-18

Abstract excerpt

<h4>ABSTRACT</h4> The impact of HSD3B1 (1245 A>C) polymorphism on clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone remains under debate. We investigated how HSD3B1 genotypes influence serum levels of testosterone, dehydroepiandrosterone sulfate (DHEA-S), abiraterone, delta-4-abiraterone (D4A) and clinical outcomes of mCRPC patients treated with ab...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
addb4fe8-d7be-59e5-a158-91f06bda7e47
DOI
10.1101/2025.09.17.25335890
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
<i>HSD3B1</i> genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisoneDOI 10.1101/2025.09.17.25335890
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesSemantic proximity
Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.Semantic proximity
Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Semantic proximity
HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.Semantic proximity
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.Semantic proximity
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.Semantic proximity
HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and BeyondSemantic proximity
HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.Semantic proximity
Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity
Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.Semantic proximity
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.Semantic proximity
Select a neighboring publication to make it the new centre.